Use our guide to learn which trials are right for you!

Study of Deferoxamine Mesylate in Intracerebral Hemorrhage

The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate,
improves the outcome of patients with brain hemorrhage.

The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of
sufficient promise to improve outcome before pursuing a larger clinical trial to examine its
effectiveness as a treatment for intracerebral hemorrhage.

All subjects will be followed for 6 months and will receive standard of care therapy while
participating in the study.

Throughout the study, we will continue to assess the safety of DFO. At the conclusion of the
study, the proportion of DFO-treated subjects with a good clinical outcome at 3 months
(defined as modified Rankin Scale (mRS) score of 0-2) will be compared to the placebo
proportion in a futility analysis to determine if it is futile to move DFO forward to Phase
III efficacy evaluation.

Inclusion Criteria:

- Age ≥ 18 and ≤ 80 years

- The diagnosis of ICH is confirmed by brain CT scan

- NIHSS score ≥6 and GCS >6 upon presentation

- The first dose of the study drug is expected to be administered within 24h of ICH
symptom onset

- Functional independence prior to ICH, defined as pre-ICH mRS ≤1

- Signed and dated informed consent is obtained.

Exclusion Criteria:

- Previous chelation therapy or known hypersensitivity to DFO products